Company intelligence / Profile preview
Antido Therapeutics
Melbourne, Victoria, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
AT-0174, a dual IDO1/TDO2 inhibitor for solid tumors (including glioblastoma, NSCLC, SCLC, and others) is in Phase 1 clinical trials and has shown synergistic activity with temozolomide in glioblastoma animal models. Additional pipeline programs include ATI-1013 (anti-nicotine monoclonal antibody) and ATI-3009 (nicotine-degrading enzyme) for rare vascular disease and nicotine addiction, both at preclinical or lead optimization stages.
- Therapeutic areas
- CardiovascularOncologyPsychiatry
- Modalities
- Small moleculeMonoclonal antibodyEnzyme
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Explicyte Immuno-OncologySylvester Comprehensive Cancer Center, University of Miami
Beyond the preview
Go deeper on Antido Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antido Therapeutics.